

# Pfizer Independent Medical Education Request for Proposals (RFP)

## BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma

Competitive Grant Program – Pfizer Internal Review Process



### Overview

This RFP seeks to support medical educational projects for healthcare professionals to enhance the care provided to multiple myeloma (MM) patients, focusing on diagnosis, treatment, comprehensive care, and social support.



### Geographic Scope/Location of Project

Japan



### Project Types and Area of Interest

Applicants should identify and address educational needs, barriers, and gaps in caring for patients with MM that require the use of BCMA-directed bispecific antibody therapies. Proposed activities should aim to enhance clinical expertise and proficiency in MM patient care. Projects may encompass interactive learning such as case conferences, workshops, and digital platforms. They may also involve visiting scholars, mentorships, collaborative partnerships, and live programs such as symposia.



### Key Milestones

- Application submission deadline: **July 30, 2024**
- Anticipated decision notification date: **October 31, 2024**



### Funding Range and Project Length

- Individual projects requesting up to 7,000,000 JPY will be considered.
- Anticipated approximate projects start and end dates: December 2024 – May 2026

## I. Eligibility

---

### Geographic Scope/Location of Project:

- Japan

### Applicant Eligibility Criteria

- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

## II. Requirements

---

### Date RFP Issued:

- June 19, 2024

### Clinical Area:

- Oncology-Hematology-Multiple Myeloma

### General Area of Interest for this RFP:

- Multiple myeloma, once considered incurable, has seen significant advancements in treatment with the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibody drugs<sup>1</sup>. However, patients who experience disease progression after these treatments still have a poor prognosis. Immunotherapies targeting B-cell maturation antigen (BCMA) have expanded treatment options, but there are concerns about the lack of expertise and information regarding these therapies<sup>2</sup>. It is crucial to address challenges such as establishing standard of care, managing adverse effects, and optimizing drug administration schedules through continuous medical education and information sharing.
- Pfizer is seeking proposals for educational projects that address various aspects of multiple myeloma care. The topics below are suggestions, and we also welcome applications related to other relevant areas:
  - Strategies for treatment administration
  - Transitioning care from inpatient to outpatient settings

- Understanding clinical data, including insights into efficacy, dosing, and side effect profile
  - Identification and management strategies for treatment-specific adverse events (AEs) in addition to associated risk factors
  - Clinical insights on using bispecific antibodies in multiple myeloma treatment
  - Addressing disparities in care and exploring opportunities to enhance the quality and equitable access to MM treatment for underserved patient populations
- Activity formats that will be considered include case conferences, workshops, digital platforms, visiting scholars, mentorships, and collaborative partnerships. One possible format would be a live symposium.
- It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. In addition, it is not also our intent to support guideline development (e.g., clinical treatment guidelines) due to the potential perception of Conflict of Interest (COI.)

#### Target Audience:

- Physicians, nurses, pharmacists, clinical laboratory technologists and other health care professionals involved in testing, diagnosis, treatment, comprehensive care, and social support for patients with multiple myeloma.

#### Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to 7,000,000 JPY will be considered.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

#### Key Dates:

- RFP release date: June 19, 2024  
Grant Application due date: July 30, 2024  
Please note the deadline is 23:59 Eastern Standard Time (New York, GMT -5).
- Anticipated Grant Award Notification Date: October 31, 2024
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: December 2024 to May 2026

#### How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- [www.cybergrants.com/pfizer/IndependentMedEd](http://www.cybergrants.com/pfizer/IndependentMedEd) and sign in. First-time users should click "Create your password".
- Click the "Start a New Independent Medical Education Application" button.
- In the application:
  - For the question "What type of request are you submitting?" select Response to a Request for Proposal (RFP)
  - For the question "Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?" select Yes
- Select the following Competitive Grant Program Name: 2024 ONC JP: BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma IME

- Select the following Primary Area of Interest: Oncology - Hematologic – Multiple Myeloma
- Requirements for submission:  
Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.

#### Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Akihiro Kamina (meg.japan@pfizer.com), with the subject line “BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma.”

#### Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer International LLC. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer and, if approved, payment will be sent from the United States.

#### Review and Approval Process:

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

#### Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

#### References:

1. James R. Berenson MSD Manual Professional Edition <https://www.msmanuals.com/en-jp/professional/hematology-and-oncology/plasma-cell-disorders/multiple-myeloma>
2. Ishida, S. (2022). Future Treatment Strategies for Multiple Myeloma. *Clinical Hematology*, 63(6), 635-645.

#### About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an

internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## Appendix

---

### General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

#### Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

#### Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

#### Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

#### Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

#### Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

#### Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

#### Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

#### Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

## Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

## Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

## Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.